# Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

> **NCT01276288** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 23 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773
- **DRUG:** hydrochlorothiazide
- **DRUG:** torasemide
- **DRUG:** BI 10773
- **DRUG:** torasemide
- **DRUG:** BI 10773
- **DRUG:** hydrochlorothiazide

## Key facts

- **NCT ID:** NCT01276288
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-06
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276288, "Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01276288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*